Groups	Ν	circCRIM1 expression / β-actin	<i>P</i> value
Normal ovarian tissues	24	0.128±0.050	0.001
ovarian cancer tissues	130	0.914±0.223	

## Supplemental Table 1: circCRIM1 expression in normal ovarian and ovarian cancer tissues

Bold and Italics means P < 0.05.

Groups	Ν	CRIM1 expression / β-actin	P value
Normal ovarian tissues	24	0.238±0.063	0.015
Ovarian cancer tissues	130	0.992±0.299	

## Supplemental Table 2: CRIM1 expression in normal ovarian and ovarian cancer tissues

Bold and Italics means P < 0.05.

Clinicopathological features	Ν	circCRIM1 expression / β-actin	P value
The pathology types			0.254
Serous carcinoma	101	$0.780 \pm 0.256$	
The other pathology types	29	$1.382 \pm 0.454$	
Age			1.000
≤ 52	67	0.914 ±0.316	
> 52	63	0.915 ±0.319	
FIGO stages			0.067
I-II	44	0.471 ±0.172	
III-IV	85	1.155 ±0.328	
Pathology classification			0.464
Well+Mod	28	$0.636 \pm 0.238$	
Poor	99	$0.898 \pm 0.266$	

**Supplemental Table 3:** Correlation of circCRIM1 expression with different clinicopathological features of ovarian cancer

Bold and Italics means P < 0.05, one ovarian cancer patient lacks information on stage, and three lack information on differentiation.

Clinicopathological features	Ν	CRIM1 expression / β-actin	P value
The pathology types			0.338
Serous carcinoma	101	$0.839 \pm 0.342$	
The other pathology types	29	$1.526 \pm 0.621$	
Age			0.914
≤ 52	67	$1.023 \pm 0.461$	
> 52	63	$0.959 \pm 0.380$	
FIGO stages			0.110
I-II	44	$0.475 \pm 0.202$	
III-IV	85	1.261 ±0.444	
Pathology classification			0.073
Well+Mod	28	$0.348 \pm 0.102$	
Poor	99	1.023±0.359	

**Supplemental Table 4:** Correlation of CRIM1 expression with different clinicopathological features of ovarian cancer

Bold and Italics means P < 0.05, one ovarian cancer patient lacks information on stage, and three lack information on differentiation.

**Supplemental Table 5:** circCRIM1 expression plasmid construction (The bold area are circCRIM1 sequences)

GGGAATGGAGCTATATAGCAGAGCTCGTTTAGTGACCGTCAGATCGCCTGGAGACGCCATC CACGCTGTTTTGACCTCCATAGAAGACACCGACTCTACTAGAGGATCTATTTCCGGTGAATT CAAAGTGCTGAGATTACAGGCGTGAGCCACCACCCCCGGCCCACTTTTTGTAAAGGTACGT <u>ACTAATGACTTTTTTTTTTTTATACTTCAG</u>ATGAGAACTGGACTGATGACCAACTGCTTGGTT TTAAACCATGCAATGAAAACCTTATTGCTGGCTGCAATATAATCAATGGGAAATGTGAA TGTAACACCATTCGAACCTGCAGCAATCCCTTTGAGTTTCCAAGTCAGGATATGTGCC TTTCAGCTTTAAAGAGAATTGAAGAAGAGAAGCCAGATTGCTCCAAGGCCCGCTGTG TCCTGGGGAGTGCTGTCCCTTACCCAGCCGCTGCGTGTGCAACCCCGCAGGCTGTCT GCGCAAAGTCTGCCAGCCGGGAAACCTGAACATACTAGTGTCAAAAGCCTCAGGGAA GCCGGGAGAGTGCTGTGACCTCTATGAGTGCAAACCAGTTTTCGGCGTGGACTGCAG GACTGTGGAATGCCCTCCTGTTCAGCAGACCGCGTGTCCCCCGGACAGCTATGAAAC **TCAAGTCAGACTAACTGCAGATGGTTGCTGTACTTTGCCAACAAG**GTAAGAAGCAAGG AAAAGAATTAGGCTCGGCACGGTAGCTCACACCTGTAATCCCAGCAGGATCCATCGATACT AGTAAGGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTC CCCGAGAAGTTGGGGGGGGGGGGGGGGCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGGTGGGG

Supplemental Table 6: The sequences of shRNA targeting circCRIM1 (The bold area are the target sequences) sh1-circCRIM1 Top strand: GATCCGTGCCAACAAGATGAGAACTGGACTTCAAGAGAGTCCAGTTCTCATCTTGTTG GCATTTTTC Bottom strand: AATTGAAAAATGCCAACAAGATGAGAACTGGACTCTCTTGAAGTCCAGTTCTCATCT TGTTGGCACG

sh2-circCRIM1 Top strand: GATCCGACTTTGCCAACAAGATGAGAACTGTTCAAGAGACAGTTCTCATCTTGTTGGC AAAGTTTTTTTC Bottom strand: AATTGAAAAAACTTTGCCAACAAGATGAGAACTGTCTCTTGAACAGTTCTCATCTTG TTGGCAAAGTCG **Supplemental Table 7:** circCRIM1-FLAG expression plasmid construction (The bold area are 3×flag sequences)

**Supplemental Table 8:** The introduced sequences of 188aa-flag plasmid (The bold area are 3×flag sequences)

ATGGTTGCTGTACTTTGCCAACAAGATGAGAACTGGACTGATGACCAACTGCTTGGTTTTAAACCATGCAAT GAAAACCTTATTGCTGGCTGCAATATAATCAATGGGAAATGTGAATGTAACACCATTCGAACCTGCAGCAATC CCTTTGAGTTTCCAAGTCAGGATATGTGCCTTTCAGCTTTAAAGAGAATTGAAGAAGAAGAGAAGCCAGATTGCT CCAAGGCCCGCTGTGAAGTCCAGTTCTCTCCACGTTGTCCTGAAGATTCTGTTCTGATCGAGGGTTATGCTCC TCCTGGGGAGTGCTGTCCCTTACCCAGCCGCTGCGTGTGCAACCCCGCAGGCTGTCTGCGCAAAGTCTGCC AGCCGGGAAACCTGAACATACTAGTGTCAAAAGCCTCAGGGAAGCCGGGAGAGTGCTGTGACCTCTATGA GTGCAAACCAGTTTTCGGCGTGGACTGCAGGACTGTGGAATGCCCTCTGTTCAGCAGACCGCGTGTCCCC CGGACAGCTATGAAACTCAAGTCAGACTAACTGCAGATGGTTGCTGTACTTTGCCAACAAGAGACCTACA AGCATGACGATGACAAGTCAGACTAACTGCAGATGGTTGCTGTACTTTGCCAACAAGAGACCTACA AGGATGACCGATGACAAGGATTACAAAGACCGACGATGATAAGGACTATAAGGATGAT GACGACAAATGA

## Supplemental Table 9: The detail of primer sequences

Names	Sequences	
circ primer —	L 5'-agtgctgtgacctctatga-3'	
	R 5'-ctggcttctcttcttcaattc-3'	
convergent primer1	L 5'-acatctgtcgctgtaagaa-3'	
	R 5'-catttcccgtccattgaga-3'	
convergent primer2	L 5'-gtgctgtcccttaccca-3'	
	R 5'-cagtccacgccgaaa-3'	
mRNA primer	L 5'-ctctggcttatgtggtttcc-3'	
	R 5'-cgcaggctggctttgt-3'	



## Supplemental Figure 1: CircCRIM1 is derived from CRIM1 by back-splicing

CircCRIM1 was generated from exon2-4 of CRIM1 (a). Sanger sequencing verified the back-splicing junction of circCRIM1 (b). CircCRIM1 was more resistant to RNase R than CRIM1 and 18s (c). CircCRIM1 was only derived from RNA but not DNA (d). Three separate experiments were conducted; Data are shown as the mean  $\pm$  SD. \*P < 0.05, \*\*P<0.01, \*\*\*P<0.001 and \*\*\*\*P<0.0001.